AI Article Synopsis
- The study examined the rates of Paxlovid prescriptions in patients under 23, using electronic health records from a large pediatric network.
- Out of over 1.4 million patients, only 920 received prescriptions, mainly aged 18-23, with most prescriptions given after April 2022.
- A significant portion of these patients had chronic health conditions, but many didn't have documented COVID-19 infections before receiving the medication, indicating a need for improved prescribing practices for children.
Article Abstract
Objective: This study was conducted to identify rates of pediatric nirmatrelvir/ritonavir (Paxlovid) prescriptions overall and by patient characteristics.
Methods: Patients up to 23 years old with a clinical encounter and a nirmatrelvir/ritonavir (Paxlovid, n/r) prescription in a PEDSnet-affiliated institution between December 1, 2021 and September 14, 2022 were identified using electronic health record (EHR) data.
Results: Of the 1,496,621 patients with clinical encounters during the study period, 920 received a nirmatrelvir/ritonavir prescription (mean age 17.2 years; SD 2.76 years). 40% (367/920) of prescriptions were provided to individuals aged 18-23, and 91% (838/920) of prescriptions occurred after April 1, 2022. The majority of patients (70%; 648/920) had received at least one COVID-19 vaccine dose at least 28 days before nirmatrelvir/ritonavir prescription. Only 40% (371/920) of individuals had documented COVID-19 within the 0 to 6 days prior to receiving a nirmatrelvir/ritonavir prescription. 53% (485/920) had no documented COVID-19 infection in the EHR. Among nirmatrelvir/ritonavir prescription recipients, 64% (586/920) had chronic or complex chronic disease and 9% (80/920) had malignant disease. 38/920 (4.5%) were hospitalized within 30 days of receiving nirmatrelvir/ritonavir.
Conclusion: Clinicians prescribe nirmatrelvir/ritonavir infrequently to children. While individuals receiving nirmatrelvir/ritonavir generally have significant chronic disease burden, a majority are receiving nirmatrelvir/ritonavir prescriptions without an EHR-recorded COVID-19 positive test or diagnosis. Development and implementation of concerted pediatric nirmatrelvir/ritonavir prescribing workflows can help better capture COVID-19 presentation, response, and adverse events at the population level.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810217 | PMC |
| http://dx.doi.org/10.1101/2022.12.23.22283868 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
US Real-World Effectiveness Study of Nirmatrelvir/Ritonavir in Preventing Hospitalization of High-Risk COVID-19 Patients.
Curr Ther Res Clin Exp
August 2024
Global Medical Epidemiology, Worldwide Medical and Safety, Pfizer Inc, Collegeville, Pennsylvania.
Purpose: We describe nirmatrelvir/ritonavir (NMV/r) effectiveness in preventing hospitalization among COVID-19 patients at high risk of severe disease.
Methods: An ongoing US population-based observational cohort study with retrospective and prospective collection of national electronic healthcare data collected from the US Optum® deidentified COVID-19 Electronic Health Record dataset during December 22, 2021-July 20, 2022. Participants were ≥12 years old; had a positive SARS-CoV-2 test, COVID-19 diagnosis, or NMV/r prescription; and were at high risk of severe COVID-19 based on demographic/clinical characteristics.
A Retrospective Claims Data Analysis on the Burden of COVID-19-Related Hospitalization in Adults at High Risk for Severe Disease Progression in Germany.
Infect Dis Ther
December 2024
Pfizer Pharma GmbH, Berlin, Germany.
Introduction: Individuals at increased risk of severe coronavirus disease 2019 (COVID-19) progression have a higher probability of being hospitalized. Nirmatrelvir/ritonavir (NMV/r) is an antiviral drug aiming to prevent severe disease courses. Our study aimed to assess the resource utilization and costs of adults hospitalized for COVID-19 at high risk for severe disease progression.
View Article and Find Full Text PDFInappropriate Prescribing of Nirmatrelvir/Ritonavir in Solid Organ Transplantation With COVID-19 Infection: A Multicenter Retrospective Study.
Clin Ther
November 2024
Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China; National Alliance of Transplant Pharmacists, Beijing, China.
Background: Nirmatrelvir-ritonavir (NR) has demonstrated effectiveness in halting the progression to severe coronavirus disease 2019 (COVID-19) among solid organ transplant recipients (SOTRs) infected with Severe Acute Respiratory Syndrome Coronavirus 2. However, it has a wide range of interactions, especially with immunosuppressants. The study aimed to comprehensively evaluate the Inappropriate prescribing of NR and immunosuppressants in SOTRs with COVID-19, while also highlighting the essential aspects.
View Article and Find Full Text PDFOpportunities and challenges associated with the launch of nirmatrelvir/ritonavir (Paxlovid) in British Columbia during the COVID-19 pandemic: A qualitative study to explore community pharmacists' perspectives.
Can Pharm J (Ott)
November 2024
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC.
Background: In February 2022, a novel antiviral for the treatment of COVID-19, nirmatrelvir/ritonavir (Paxlovid), was approved by Health Canada and made available to patients in British Columbia (BC). BC community pharmacists did not prescribe nirmatrelvir/ritonavir, but dispensing involved a detailed assessment with close attention to drug-drug interactions and patient monitoring. As the nirmatrelvir/ritonavir service was unique in BC, and not all pharmacists participated in the program, it is important to evaluate the perspectives of all the pharmacists who were affected so that lessons learned from the program can inform future pandemic planning and government initiatives.
View Article and Find Full Text PDFSelected Acute Safety Events Following the Use of Nirmatrelvir/Ritonavir or Molnupiravir for COVID-19: A Nationwide Cohort Study in South Korea.
Clin Pharmacol Ther
October 2024
School of Pharmacy, Sungkyunkwan University, Suwon, Korea.
Article Synopsis
- A study was conducted to evaluate the safety of COVID-19 treatments nirmatrelvir/ritonavir (NMVr) and molnupiravir (MOL) by comparing acute complications in treated versus untreated patients.
- Data from nationwide databases were used to analyze results from over 700,000 NMVr users and over 150,000 MOL users, focusing on specific cardiac and neurological events.
- The findings revealed that both NMVr and MOL users had a lower risk of certain serious side effects like atrial fibrillation and dysgeusia, suggesting these treatments may be effective in reducing acute complications linked to COVID-19.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!